Q1 FY27 earnings call · August 05, 2026

Sudeep Pharma Ltd (SUDEEPPHRM) Q1 FY27 Earnings Call: Bisglycinate Sales Surpass Full-Year FY26 Total, Battery Customer Funnel Expands to Eight

Cofacto ResearchPublished August 05, 20265 min read
Quick summary

Sudeep Pharma Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue up 27% YoY; margins resilient despite LPG disruption

  • Revenue of Rs.158.3 crore in Q1 FY 2026-2027, up 27% YoY from Rs.124.9 crore in Q1 FY 2025-2026, driven by broad-based growth across pharma, food & nutrition, and specialty ingredients.
  • EBITDA of Rs.54.9 crore in Q1 FY 2026-2027, up 25% YoY; EBITDA margin held at 34.7% despite severe LPG supply crisis that pushed April utilization to ~33% of normal.
  • PAT of Rs.40.6 crore in Q1 FY 2026-2027, from Rs.31.3 crore in Q1 FY 2025-2026; PAT margin improved to 25.6% from 25.0%.
  • Pharma, Food & Nutrition segment contributed 69% of Q1 FY 2026-2027 revenue; Specialty Ingredients contributed 31%. Exports remained the dominant revenue driver.
  • Management expects strong momentum to continue into Q2 FY 2026-2027, with a historically stronger second half supporting "a year of strong growth for FY 2026-2027".

Bisglycinate surges; battery funnel expands to 8 customers

  • Bisglycinate sales in Q1 FY 2026-2027 surpassed the entire FY 2025-2026 total; management expects it to become a top-two or top-three product though material contribution is not expected in FY 2026-2027.
  • Pharma, Food & Nutrition segment grew 30% YoY in Q1 FY 2026-2027, predominantly volume-driven (~3% from currency). Management views this growth rate as sustainable at scale in FY 2027-2028 once new greenfield capacity is fully utilized.
  • Specialty Ingredients grew 19% YoY in Q1 FY 2026-2027, below trend due to LPG shortage; normalized operations resumed in Q2 FY 2026-2027, and historical growth trajectory is expected to resume.
  • Battery materials customer funnel expanded from six to eight customers for iron phosphate (LFP chemistry) as of Q1 FY 2026-2027; management emphasized the need to convert approvals into binding orders.
  • Two additional strategic MOUs signed in Q1 FY 2026-2027 with leading South Korean cathode active material manufacturers and their cell manufacturing partners.
  • China's Decree 837 cited by management as reinforcing "the strategic importance of non-China suppliers for the battery supply chain".

EBITDA target of 37-38%; specialty margins compressed by NSS headwind

  • EBITDA margin target of 37-38% — management aims to sustain this range, supported by international markets with stronger margin profiles; historically achieved before sales team investments.
  • Specialty segment margins fell to 26% in Q1 FY 2026-2027 due to sub-50% utilization for half the quarter and a challenging quarter for the NSS (European subsidiary) business. Core specialty business (ex-NSS) maintained margins in the mid-30s.
  • NSS customer issue — a major infant formula client in Ireland scaled down operations due to the energy crisis, delaying purchase orders. Management expects "flattish to single-digit growth for NSS in FY 2026-2027".
  • NSS margins expected to track Indian specialty levels by FY 2027-2028 as new projects materialize and revenue grows; a new sales head has been hired to expand beyond Ireland.
  • Cost pass-through for phosphates had marginal benefit in Q1 FY 2026-2027; the majority of sales with pass-through are expected in Q2 FY 2026-2027. Phosphoric acid prices rose ~50% during the quarter.
  • Working capital target of 160-170 days steady-state (excluding battery inventory); long-term sustainable target of 150 days. Near-term inventory days elevated due to geopolitical logistics delays and battery material inventory build.

Battery scale-up; greenfield facility and LFP capacity roadmap

  • Sudeep Advanced Materials (SAM) Phase 1 commissioning targeted by April 2027; major long-lead equipment deliveries expected by October 2026. Customer qualification funnel: 21 at lab validation, 16 at pilot scale, 7 completed commercial validation with active off-take discussions.
  • Management optimistic about concluding two significant binding off-take agreements later in FY 2026-2027; early evaluation of expansion from 100 KTPA to 200 KTPA underway.
  • For the new 21,000 ton greenfield facility, management guided for approximately one-third utilization in FY 2028-2029, with a "hockey stick" in utilization expected by FY 2029-2030.
  • Management believes LFP will be the dominant battery chemistry for the next 5-7 years (FY 2026-2033), but noted that even if sodium-ion scales, it will require iron phosphate as a precursor, providing dual application for their product.
  • At scale, steady-state asset turns for greenfield and battery facilities are expected to settle between 2.7x and 3.0x (period unspecified).
  • New capacity will allocate ~50% to expand existing phosphate products and introduce new products (big glycinate, gluconate, citrate). Management expects to return to 37-38% EBITDA margins with ramp-up of new greenfield capacity.

Capacity inflection in H2 FY27; NSS drag near-term

  • PFN capacity is nearly fully utilized — current capacity can be sweated for only a "couple of percent" additional growth; the next growth inflection depends on the greenfield facility being commissioned in Q3 FY 2026-2027.
  • Greenfield facility at Navsari is undergoing regulatory approvals; FDA approval expected in Q2 FY 2026-2027, with commercial supplies starting in Q3 FY 2026-2027.
  • NSS is expected to contribute flattish to single-digit growth in FY 2026-2027; management indicated that "historical growth momentum in specialty ingredients is sustainable for FY 2026-2027 and FY 2027-2028".
  • Management evaluating scale-up from 100,000 to 200,000 KTPA capacity, contingent on binding offtake agreements with two large customers. Current target to reach 200 KTPA between calendar years 2030 and 2031.
  • Optimum steady-state capacity utilization is 70-75%, depending on product mix (period unspecified).
  • Logistics disruptions, elevated freight costs, and 50% increase in phosphoric acid prices were key headwinds in Q1 FY 2026-2027; price increases expected to largely offset input cost impact in Q2 FY 2026-2027.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.